These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12560568)

  • 1. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
    Hanke T; Barnfield C; Wee EG; Ågren L; Samuel RV; Larke N; Liljeström P
    J Gen Virol; 2003 Feb; 84(Pt 2):361-368. PubMed ID: 12560568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
    Cebere I; Dorrell L; McShane H; Simmons A; McCormack S; Schmidt C; Smith C; Brooks M; Roberts JE; Darwin SC; Fast PE; Conlon C; Rowland-Jones S; McMichael AJ; Hanke T
    Vaccine; 2006 Jan; 24(4):417-25. PubMed ID: 16176847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
    Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
    J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a DNA-MVA/HIVA vaccine for Kenya.
    Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
    Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
    Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
    Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
    Mwau M; Cebere I; Sutton J; Chikoti P; Winstone N; Wee EG; Beattie T; Chen YH; Dorrell L; McShane H; Schmidt C; Brooks M; Patel S; Roberts J; Conlon C; Rowland-Jones SL; Bwayo JJ; McMichael AJ; Hanke T
    J Gen Virol; 2004 Apr; 85(Pt 4):911-919. PubMed ID: 15039533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of BCG.HIVA
    Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
    Rosario M; Hopkins R; Fulkerson J; Borthwick N; Quigley MF; Joseph J; Douek DC; Greenaway HY; Venturi V; Gostick E; Price DA; Both GW; Sadoff JC; Hanke T
    J Virol; 2010 Jun; 84(12):5898-908. PubMed ID: 20375158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.
    Saubi N; Mbewe-Mvula A; Gea-Mallorqui E; Rosario M; Gatell JM; Hanke T; Joseph J
    PLoS One; 2012; 7(8):e42559. PubMed ID: 22927933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
    Hanke T; McMichael AJ; Dorrell L
    J Gen Virol; 2007 Jan; 88(Pt 1):1-12. PubMed ID: 17170430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
    Im EJ; Nkolola JP; di Gleria K; McMichael AJ; Hanke T
    Eur J Immunol; 2006 Oct; 36(10):2574-84. PubMed ID: 17013988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation: DNA/MVA prime-boost HIV vaccine.
    Kent S; De Rose R; Rollman E
    Curr Opin Investig Drugs; 2007 Feb; 8(2):159-67. PubMed ID: 17328232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
    Rosario M; Fulkerson J; Soneji S; Parker J; Im EJ; Borthwick N; Bridgeman A; Bourne C; Joseph J; Sadoff JC; Hanke T
    J Virol; 2010 Aug; 84(15):7815-21. PubMed ID: 20484495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.
    Nilsson C; Mäkitalo B; Berglund P; Bex F; Liljeström P; Sutter G; Erfle V; ten Haaft P; Heeney J; Biberfeld G; Thorstensson R
    Vaccine; 2001 May; 19(25-26):3526-36. PubMed ID: 11348720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
    Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
    J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.
    Nkolola JP; Wee EG; Im EJ; Jewell CP; Chen N; Xu XN; McMichael AJ; Hanke T
    Gene Ther; 2004 Jul; 11(13):1068-80. PubMed ID: 15164090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
    Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
    J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
    García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
    J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.